Fig. 2From: Inhibition of effector B cells by ibrutinib in systemic sclerosisRelative changes of cytokine production under ibrutinib treatment. B cells of patients with SSc (n = 5) were treated with ibrutinib (0.1 μM, 1 μM, 10 μM). The relative change in cytokine production compared to control is depicted. Low concentrations of ibrutinib (0.1 μM, 1 μM) reduce TNF-α and IL-6 significantly but do not alter the level of IL-10. High concentrations of ibrutinib (10 μM) reduce cytokine production nonspecifically. Bars indicate the mean. Error bars show SEM. *p < 0.05, **p < 0.01Back to article page